<DOC>
	<DOCNO>NCT00475969</DOCNO>
	<brief_summary>To see duloxetine 60 120 mg daily ( QD ) good placebo treatment generalize anxiety disorder ( GAD ) .</brief_summary>
	<brief_title>Duloxetine v Placebo Treatment General Anxiety</brief_title>
	<detailed_description>duloxetine 60 120 mg daily ( QD ) placebo 11 week</detailed_description>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Male female outpatient least 18 year age present generalize anxiety disorder ( GAD ) base disease diagnostic criterion The patient must suffer GAD adjustment disorder anxiety disorder otherwise specify ( NOS ) . Symptoms GAD situational nature . Females childbearing potential ( surgically sterilize menarche 1 year postmenopause ) breastfeeding ; test negative pregnancy time enrollment base urine pregnancy test ; agree use reliable method birth control study 1 week follow last dose study drug . Must Clinical Global Impressions Severity ( CGISeverity ) score great equal 4 Visit 1 Visit 2 . At Visit 1 , patient must Covi Anxiety Scale ( CAS ) score great equal 9 , item Raskin Depression Scale ( RDS ) may great 3 , CAS must great RDS . Must Hospital Anxiety Depression Scale ( HADS ) anxiety subscale score great equal 10 Visit 1 . Any current primary DSMIV Axis I diagnosis GAD . Patients diagnose history major depressive disorder ( MDD ) within past 6 month Patients diagnose history Panic Disorder , PostTraumatic Stress Disorder ( PTSD ) , eat disorder within past year Patients diagnose Obsessive Compulsive Disorder ( OCD ) , Bipolar Affective Disorder , psychosis , factitious disorder , somatoform disorder lifetime . The presence Axis II disorder history antisocial behavior , , judgment investigator , would interfere compliance study protocol . Benzodiazepine use 14 day prior Visit 2 . Patients judge clinically serious suicidal risk , patient , opinion investigator , poor medical psychiatric risk study completion . Have receive treatment within last 30 day drug ( include study drug ) receive regulatory approval indication time study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>